Comparing Brukinsa vs Imbruvica
| Brukinsa (zanubrutinib) | Imbruvica (ibrutinib) |
|
|---|
| Brukinsa (zanubrutinib) | Imbruvica (ibrutinib) |
|
|||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Prescribed for Waldenström Macroglobulinemia, Chronic Lymphocytic Leukemia, Marginal Zone Lymphoma, Mantle Cell Lymphoma, Follicular Lymphoma. Brukinsa may also be used for purposes not listed in... View more |
Prescription only
Imbruvica is an oral tablet that may be taken once daily to treat certain types of cancers in adults or to treat chronic Graft Versus Host disease in adults and children older than 1 year. It works... View more |
Related suggestions Waldenström Macroglobulinemia
|
|||||||||||||||
| More about Brukinsa (zanubrutinib) | More about Imbruvica (ibrutinib) | ||||||||||||||||
| Ratings & Reviews | |||||||||||||||||
|
Brukinsa has an average rating of 8.6 out of 10 from a total of 43 ratings on Drugs.com. 77% of reviewers reported a positive effect, while 0% reported a negative effect. |
Imbruvica has an average rating of 6.6 out of 10 from a total of 69 ratings on Drugs.com. 59% of reviewers reported a positive effect, while 30% reported a negative effect. |
||||||||||||||||
| Side Effects Experienced by Users Side effects are reported in Drugs.com user reviews and not clinically verified. | |||||||||||||||||
|
View all Brukinsa side effects |
View all Imbruvica side effects |
||||||||||||||||
| Drug Class | |||||||||||||||||
| Generic Availability | |||||||||||||||||
| Pricing and Coupons * Prices are without insurance | |||||||||||||||||
View all Brukinsa prices |
View all Imbruvica prices |
||||||||||||||||
| Dosage Forms | |||||||||||||||||
|
|
||||||||||||||||
| Brand Names | |||||||||||||||||
|
N/A |
N/A |
||||||||||||||||
| Half Life Drug half-life is the time required for plasma concentration to reduce to half its original value. | |||||||||||||||||
|
4 hours |
6 hours |
||||||||||||||||
| CSA Schedule 1 View glossary of CSA terms | |||||||||||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||
| Pregnancy Category | |||||||||||||||||
|
Summary unavailable. See the full pregnancy warnings document. |
Category D
Positive evidence of risk
See the full pregnancy warnings document. |
||||||||||||||||
| Drug Interactions | |||||||||||||||||
|
A total of 527 drugs are known to interact with Brukinsa:
|
A total of 506 drugs are known to interact with Imbruvica:
|
||||||||||||||||
| Alcohol/Food/Lifestyle Interactions | |||||||||||||||||
|
|
||||||||||||||||
| Disease Interactions | |||||||||||||||||
| First Approval Date | |||||||||||||||||
|
November 14, 2019 |
November 13, 2013 |
||||||||||||||||
| WADA Class View classifications | |||||||||||||||||
|
N/A |
N/A |
||||||||||||||||
| More Information | |||||||||||||||||
| Patient Resources | |||||||||||||||||
| Professional Resources | |||||||||||||||||
| Related Treatment Guide | |||||||||||||||||
1 The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
See also:
Calquence
Calquence (acalabrutinib) is used to treat chronic lymphocytic leukemia (CLL), and mantle cell ...
Jaypirca
Jaypirca (pirtobrutinib) is a cancer medicine used to treat types of CLL, SLL, and MCL. Includes ...
Imbruvica
Imbruvica (ibrutinib) is used to treat chronic lymphocytic leukemia (CLL), small lymphocytic ...
Zanubrutinib
Zanubrutinib is a targeted treatment that may be used to treat adults with chronic lymphocytic ...
Pirtobrutinib
Pirtobrutinib is a cancer medicine used to treat types of CLL, SLL, and MCL. Includes Pirtobrutinib ...
Acalabrutinib
Acalabrutinib (Calquence) is used to treat chronic lymphocytic leukemia (CLL), and mantle cell ...
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.